Aclaris Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Aclaris Therapeutics, Inc. (ACRS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.67M, a 12.77% decline year-over-year.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $3.20M, a 9.53% decline year-over-year.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.86M, a 4.79% decline year-over-year.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.06M, a 5.51% increase year-over-year.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $12.38M, a 14.08% increase from fiscal 2024.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.86M, a 47.15% decline from fiscal 2023.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $20.54M, a 36.59% increase from fiscal 2022.
- Aclaris Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $15.04M, a 6.96% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.67M 10-Q · filed 2026-08-06 | $5.87M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $3.20M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $12.38M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $2.86M 10-Q · filed 2025-11-06 | $5.92M derived: sum of 2 quarters · filed 2026-08-06 | $9.46M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.06M 10-Q · filed 2026-08-06 | $6.60M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.54M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $10.86M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-06 | $5.91M derived: sum of 2 quarters · filed 2025-11-06 | $8.00M derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.90M 10-Q · filed 2025-11-06 | $4.99M derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $2.09M 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $20.54M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $5.95M 10-Q · filed 2024-11-06 | $12.47M derived: sum of 2 quarters · filed 2024-11-06 | $19.28M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-06-30 | $6.52M 10-Q · filed 2024-11-06 | $13.33M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-03-31 | $6.81M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $15.04M 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $4.19M 10-Q · filed 2023-11-06 | $7.88M derived: sum of 2 quarters · filed 2023-11-06 | $10.23M derived: sum of 3 quarters · filed 2023-11-06 | |
| 2022-06-30 | $3.69M 10-Q · filed 2023-11-06 | $6.04M derived: sum of 2 quarters · filed 2023-11-06 | ||
| 2022-03-31 | $2.35M 10-Q · filed 2023-11-06 | |||
| 2021-12-31 | $14.06M 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $3.70M 10-Q · filed 2022-11-08 | $7.54M derived: sum of 2 quarters · filed 2022-11-08 | $10.21M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $3.83M 10-Q · filed 2022-11-08 | $6.51M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $2.67M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $11.21M 10-K · filed 2023-02-23 | |||
| 2020-09-30 | $1.94M 10-Q · filed 2021-11-02 | $5.25M derived: sum of 2 quarters · filed 2021-11-02 | $8.70M derived: sum of 3 quarters · filed 2021-11-02 | |
| 2020-06-30 | $3.31M 10-Q · filed 2021-11-02 | $6.76M derived: sum of 2 quarters · filed 2021-11-02 | ||
| 2020-03-31 | $3.45M 10-Q · filed 2021-11-02 | |||
| 2019-12-31 | $16.18M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $3.32M 10-Q · filed 2020-11-04 | $8.13M derived: sum of 2 quarters · filed 2020-11-04 | $13.00M derived: sum of 3 quarters · filed 2020-11-04 | $17.95M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $4.81M 10-Q · filed 2020-11-04 | $9.68M derived: sum of 2 quarters · filed 2020-11-04 | $14.63M derived: sum of 3 quarters · filed 2021-02-25 | $19.34M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $4.86M 10-Q · filed 2020-11-04 | $9.82M derived: sum of 2 quarters · filed 2021-02-25 | $14.53M derived: sum of 3 quarters · filed 2021-02-25 | $19.77M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $9.66M derived: sum of 2 quarters · filed 2021-02-25 | $14.91M derived: sum of 3 quarters · filed 2021-02-25 | $20.05M 10-K · filed 2021-02-25 |
| 2018-09-30 | $4.71M 10-Q · filed 2019-11-07 | $9.96M derived: sum of 2 quarters · filed 2019-11-07 | $15.10M 10-Q · filed 2018-11-06 | $19.40M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $5.25M 10-Q · filed 2019-11-07 | $10.39M 10-Q · filed 2018-08-03 | $14.69M derived: sum of 3 quarters · filed 2020-02-25 | $18.36M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $5.14M 10-Q · filed 2019-11-07 | $9.44M derived: sum of 2 quarters · filed 2020-02-25 | $13.12M derived: sum of 3 quarters · filed 2020-02-25 | $16.42M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $7.97M derived: sum of 2 quarters · filed 2020-02-25 | $11.28M derived: sum of 3 quarters · filed 2020-02-25 | $14.43M 10-K · filed 2020-02-25 |
| 2017-09-30 | $3.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $6.98M derived: sum of 2 quarters · filed 2017-11-07 | $10.13M 10-Q · filed 2017-11-07 | $12.04M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $6.46M 10-Q · filed 2017-08-08 | $8.37M derived: sum of 3 quarters · filed 2019-03-18 | $9.98M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-03-31 | $3.15M 10-Q · filed 2017-05-09 | $5.06M derived: sum of 2 quarters · filed 2019-03-18 | $6.68M derived: sum of 3 quarters · filed 2019-03-18 | $8.04M derived: sum of 4 quarters · filed 2019-03-18 |
| 2016-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $3.53M derived: sum of 2 quarters · filed 2019-03-18 | $4.88M derived: sum of 3 quarters · filed 2019-03-18 | $6.10M 10-K · filed 2019-03-18 |
| 2016-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $2.97M derived: sum of 2 quarters · filed 2016-11-03 | $4.19M 10-Q · filed 2016-11-03 | $4.84M derived: sum of 4 quarters · filed 2018-03-12 |
| 2016-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $2.58M 10-Q · filed 2016-08-11 | $3.22M derived: sum of 3 quarters · filed 2018-03-12 | |
| 2016-03-31 | $1.22M 10-Q · filed 2016-05-11 | $1.87M derived: sum of 2 quarters · filed 2018-03-12 | ||
| 2015-12-31 | $648.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $891.00K 10-K · filed 2018-03-12 | ||
| 2015-09-30 | $243.00K 10-Q · filed 2015-12-03 | |||
| 2014-12-31 | $27.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |